Supplementary Data DS1 from A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in &lt;i&gt;BRAF&lt;/i&gt; V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study